XML 103 R40.htm IDEA: XBRL DOCUMENT
v3.25.3

Collaborations (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended |
--- | --- | --- | ---
Sep. 30, 2025 | Sep. 30, 2024 | Sep. 30, 2025 | Sep. 30, 2024 | Dec. 31, 2024
Collaborative and license agreements |  |  |  |  |
AbbVie's receivable from Janssen | $ 12,769 |  | $ 12,769 |  | $ 10,919
AbbVie's payable to Janssen | 33,619 |  | 33,619 |  | 31,945
Janssen Biotech Inc. | Collaborative arrangement |  |  |  |  |
Collaborative and license agreements |  |  |  |  |
Milestone payments | 200 |  | $ 200 |  |
Share of collaboration development costs responsible by Janssen (as a percent) |  |  | 60.00% |  |
Share of collaboration development costs responsible by the entity (as a percent) |  |  | 40.00% |  |
Global - AbbVie's share of other costs (included in respective line items) | 24 | $ 38 | $ 74 | $ 120 |
AbbVie's receivable from Janssen | 221 |  | 221 |  | 237
AbbVie's payable to Janssen | 217 |  | 217 |  | $ 282
Janssen Biotech Inc. | Collaborative arrangement | United States |  |  |  |  |
Collaborative and license agreements |  |  |  |  |
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) | 235 | 282 | 735 | 849 |
Janssen Biotech Inc. | Collaborative arrangement | International |  |  |  |  |
Collaborative and license agreements |  |  |  |  |
International - AbbVie's share of profits (included in net revenues) | 199 | 210 | 619 | 676 |
Genentech, Inc. | Collaborative arrangement |  |  |  |  |
Collaborative and license agreements |  |  |  |  |
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) | 286 | 263 | 790 | 733 |
AbbVie's share of development costs (included in R&D) | 15 | 21 | 47 | 63 |
Genentech, Inc. | Collaborative arrangement | United States |  |  |  |  |
Collaborative and license agreements |  |  |  |  |
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) | $ 13 | $ 10 | $ 26 | $ 25 |

X
- Definition The maximum milestone payments that may be received by the entity based on the achievement of specified events under a collaborative arrangement. + References No definition available. + Details
Name: | abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable
Namespace Prefix: | abbv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the percentage of share in collaboration development costs responsible by the entity under cost sharing arrangement. + References No definition available. + Details
Name: | abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts
Namespace Prefix: | abbv_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of share in collaboration development costs responsible by Janssen under cost sharing arrangement. + References No definition available. + Details
Name: | abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty
Namespace Prefix: | abbv_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of costs of goods and services sold arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms. + References No definition available. + Details
Name: | abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements
Namespace Prefix: | abbv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of other expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms. + References No definition available. + Details
Name: | abbv_OtherExpensesFromCollaborativeArrangements
Namespace Prefix: | abbv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of research and development expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms. + References No definition available. + Details
Name: | abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements
Namespace Prefix: | abbv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of selling, general and administrative expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms. + References No definition available. + Details
Name: | abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements
Namespace Prefix: | abbv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3 + Details
Name: | us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=abbv_JanssenBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=abbv_GenentechInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |